Breast cancer. Malignant neoplasm of breast
Conditions
Interventions
Control group: tamoxifen, 20mg oral, once a day
Intervention 1: Intervention group 1: tamoxifen, 30mg oral, twice a day. Intervention 2: Intervention group 2: tamoxifen, 40mg oral, twice a day. Intervention 3: Control group: tamoxifen, 20mg oral, o
Treatment - Drugs
Intervention group 1: tamoxifen, 30mg oral, twice a day
Intervention group 2: tamoxifen, 40mg oral, twice a day
Sponsors
Isfahan University of Medical Siences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women were eligible if they were on tamoxifen 20 mg daily for at least 4 months; nonpregnant; had normal kidney, liver, and bone marrow function. Patients were excluded if they had a concurrent medication therapy with medications known to inhibit CYP2D6.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoxifen. Timepoint: After using 20mg/day tamoxifen for at least 4 month, 4 month after intervention. Method of measurement: Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: Four months after intervention. Method of measurement: Questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Khalaj
Isfahan University of Medical Siences
Outcome results
None listed